{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:24:20Z","timestamp":1787149460917,"version":"build-2736575974"},"reference-count":23,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: Colistin remains an important therapeutic option for complicated urinary tract infections (cUTIs) caused by multidrug-resistant Gram-negative bacteria. A loading dose is often recommended to rapidly achieve steady-state plasma concentrations, but its clinical benefit specifically for cUTIs, where local urinary drug concentrations markedly exceed plasma levels, remains unclear. Methods: We conducted a retrospective cohort study of adult patients treated with intravenous colistin for cUTIs at Nakornping Hospital, Chiang Mai, Thailand, between 2015 and 2022. Patients were classified as receiving loading-dose (LD) or non-loading-dose (non-LD) colistin. The primary outcome was 30-day all-cause mortality. Secondary outcomes included clinical response, microbiological response, and nephrotoxicity (defined by RIFLE criteria). Inverse probability weighting (IPW) using the propensity score was applied to adjust for baseline covariates, and Cox proportional hazards regression was used to estimate crude and adjusted hazard ratios (HR) using the non-LD group as the reference. Results: Among 123 patients (74 LD, 49 non-LD), unadjusted 30-day all-cause mortality was 35.14% versus 40.82% (p = 0.524), clinical response was 75.68% versus 71.43% (p = 0.599), and microbiological response was 78.38% versus 65.31% (p = 0.109) for LD versus non-LD, respectively. Nephrotoxicity occurred in 48.65% versus 38.78% (p = 0.281). After IPW adjustment, no statistically significant differences were observed between the LD and non-LD groups for 30-day all-cause mortality (aHR 0.78, 95% CI 0.43\u20131.42, p = 0.419), clinical response (aOR 1.48, 95% CI 0.54\u20134.08, p = 0.445), or microbiological response (aOR 2.10, 95% CI 0.81\u20135.48, p = 0.128). For the safety outcome, nephrotoxicity was analyzed using the Fine\u2013Gray competing risk model, treating death as a competing event. The IPW-adjusted subdistribution hazard ratio was (asHR) 2.23 (95% CI 0.83\u20135.95, p = 0.110), indicating no statistically significant difference in renal safety between the LD and non-LD groups. Conclusions: Loading-dose colistin was not associated with a statistically significant reduction in 30-day all-cause mortality or improvements in clinical response and microbiological eradication in patients with cUTIs. Nephrotoxicity was numerically lower without a loading dose, but the wide confidence intervals in this study of 123 patients precluded a definitive conclusion regarding renal safety. Omitting the loading dose may be a reasonable option for localized urinary infections, particularly in patients at high risk for acute kidney injury, pending confirmation in larger prospective studies.<\/jats:p>","DOI":"10.3390\/antibiotics15080812","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T13:14:01Z","timestamp":1787145241000},"page":"812","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Does a Loading Dose Improve Outcomes? Colistin Therapy for Urinary Tract Infections Caused by Multidrug-Resistant Gram-Negative Bacteria"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7665-8819","authenticated-orcid":false,"given":"Wasan","family":"Katip","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand"},{"name":"Center of Excellence in Pharmaceutical Nanotechnology, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puntapong","family":"Taruangsri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nakornping Hospital, Chiang Mai 50180, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siriporn","family":"Okonogi","sequence":"additional","affiliation":[{"name":"Center of Excellence in Pharmaceutical Nanotechnology, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand"},{"name":"Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-6576","authenticated-orcid":false,"given":"Shaun Wen Huey","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway 47500, Selangor, Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5961-8978","authenticated-orcid":false,"given":"Ajaree","family":"Rayanakorn","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/00325481.2017.1246055","article-title":"An update on the management of urinary tract infections in the era of antimicrobial resistance","volume":"129","author":"Bader","year":"2017","journal-title":"Postgrad. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/QCO.0000000000000228","article-title":"Global epidemiology of urinary tract infections","volume":"29","author":"Tandogdu","year":"2016","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1080\/00325481.2019.1680052","article-title":"Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents","volume":"132","author":"Bader","year":"2020","journal-title":"Postgrad. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clin. Infect. Dis., ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Abushanab, D., Nasr, Z.G., and Al-Badriyeh, D. (2022). Efficacy and safety of colistin versus tigecycline for multi-drug-resistant and extensively drug-resistant gram-negative pathogens\u2014A meta-analysis. Antibiotics, 11.","DOI":"10.3390\/antibiotics11111630"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1128\/AAC.01733-10","article-title":"Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients","volume":"55","author":"Garonzik","year":"2011","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jinf.2019.06.011","article-title":"Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical","volume":"79","author":"Luque","year":"2019","journal-title":"J. Infect."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2147\/IDR.S608721","article-title":"Colistin Therapy for Urinary Tract Infections Due to Multidrug-Resistant Bacteria: Experience at a Tertiary Academic Medical Center","volume":"19","author":"Aldairem","year":"2026","journal-title":"Infect. Drug Resist."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Haseeb, A., Faidah, H.S., Alghamdi, S., Alotaibi, A.F., Elrggal, M.E., Mahrous, A.J., Almarzoky Abuhussain, S.S., Obaid, N.A., Algethamy, M., and AlQarni, A. (2021). Dose Optimization of Colistin: A Systematic Review. Antibiotics, 10.","DOI":"10.3390\/antibiotics10121454"},{"key":"ref_10","first-page":"148","article-title":"Effectiveness and safety of colistin in multi drug resistant urinary tract infections","volume":"7","author":"Karakkattu","year":"2017","journal-title":"J. Appl. Pharm. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Katip, W., Uitrakul, S., and Oberdorfer, P. (2022). Clinical Efficacy and Nephrotoxicity of the Loading Dose Colistin for the Treatment of Carbapenem-Resistant Acinetobacter baumannii in Critically Ill Patients. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14061266"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Y\u00fcksel, C., Al\u0131ravc\u0131, I.D., Ko\u015fan, M., Esen, S., Yenice Akta\u015f, S., Kaya Terzi, N., Berber, A.A., Alkan, S., and Kaya, S. (2025). Investigation of therapeutic efficacy of intravesical tigecycline administration in rats with cystitis induced by extensively drug-resistant (XDR), tigecycline-sensitive Acinetobacter baumannii strain. Antibiotics, 14.","DOI":"10.3390\/antibiotics14060611"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/1752-1947-6-426","article-title":"Intravesical colistin irrigation to treat multidrug-resistant Acinetobacter baumannii urinary tract infection: A case report","volume":"6","year":"2012","journal-title":"J. Med. Case Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3126\/jnsccm.v4i1.88927","article-title":"Intravesical Colistin Bladder Irrigation for Multidrug Resistant Urinary Tract Infections in Critically Ill Patients with Renal Compromise: A Single-Center Case Series from Nepal","volume":"4","author":"Poudel","year":"2026","journal-title":"J. Nepal. Soc. Crit. Care Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4103\/ijn.IJN_130_20","article-title":"Colistin nephrotoxicity\u2014Age and baseline kidney functions hold the key","volume":"31","author":"Prasannan","year":"2021","journal-title":"Indian J. Nephrol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7795096","DOI":"10.1155\/2021\/7795096","article-title":"Colistin-induced acute kidney injury and the effect on survival in patients with multidrug-resistant Gram-negative infections: Significance of drug doses adjusted to ideal body weight","volume":"2021","author":"Arrayasillapatorn","year":"2021","journal-title":"Int. J. Nephrol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/14740338.2024.2416256","article-title":"Combined nephrotoxicity of Polymyxins and Vancomycin: A study on adverse event reporting for monotherapy versus combinations using the FDA adverse event reporting system (FAERS)","volume":"25","author":"Zhan","year":"2026","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_18","first-page":"60","article-title":"Study of the prevalence and factors associated with vancomycin-induced nephrotoxicity","volume":"19","author":"Nakburin","year":"2023","journal-title":"Isan J. Pharm. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"ofab026","DOI":"10.1093\/ofid\/ofab026","article-title":"Colistin nephrotoxicity: Meta-analysis of randomized controlled trials","volume":"8","author":"Eljaaly","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3855\/jidc.11413","article-title":"Colistin nephrotoxicity in critically ill patients after implementation of a new dosing strategy","volume":"13","author":"Ozel","year":"2019","journal-title":"J. Infect. Dev. Ctries."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","article-title":"International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy"},{"key":"ref_22","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2015). Performance Standards for Antimicrobial Susceptibility Testing. CLSI Supplement M100-S25, CLSI. [25th ed.]."},{"key":"ref_23","unstructured":"European Committee on Antimicrobial Susceptibility Testing (2015). Breakpoint Tables for Interpretation of MICs and Zone Diameters, EUCAST. Available online: https:\/\/www.eucast.org."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/8\/812\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T13:29:15Z","timestamp":1787146155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/15\/8\/812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":23,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["antibiotics15080812"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics15080812","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]}}}